Pharmacyte Biotech, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher report a continued passive beneficial ownership of 4.99% in PharmaCyte Biotech, Inc. as of December 31, 2025, constrained by blocker provisions.
NASDAQ
Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher have disclosed a combined beneficial ownership of 9.99% of PharmaCyte Biotech, Inc.'s common stock, as detailed in an amended Schedule 13G filing.
NASDAQ
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly reported a 9.9% beneficial ownership stake in PharmaCyte Biotech, Inc., primarily through warrants.
NASDAQ
Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed beneficial ownership of approximately 9.99% of PharmaCyte Biotech, Inc.'s common stock as of December 31, 2024, through a Schedule 13G filing.